Payment overview · 2025
General Payments
$146.03
7 reported records · 7 companies
Healthcare provider profile · identity verified
Thomas J Ullo, MD
Allopathic & Osteopathic Physicians|Family Medicine · CLEARWATER, FL · NPI 1265502355
Verified facts
What the public records show
CMS Open Payments records show Thomas J Ullo, MD received $146.03 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.90 | 16.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.18 | 15.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.39 | 14.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.09 | 14.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.27 | 13.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.64 | 12.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.56 | 12.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.03 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 621 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 473 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 309 | 94 |
| Losartan Potassium | Losartan Potassium | 273 | 83 |
| Metformin Hcl | Metformin Hcl | 256 | 74 |
| Lisinopril | Lisinopril | 241 | 76 |
| Alprazolam | Alprazolam | 235 | 52 |
| Omeprazole | Omeprazole | 206 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 50 |
| Simvastatin | Simvastatin | 166 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 29 |
| Trazodone Hcl | Trazodone Hcl | 135 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 42 |
| Gabapentin | Gabapentin | 129 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 40 |
| Tramadol Hcl | Tramadol Hcl | 118 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 102 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 37 |
| Alendronate Sodium | Alendronate Sodium | 93 | 29 |
| Clonazepam | Clonazepam | 91 | 22 |
| Furosemide | Furosemide | 88 | 33 |
| Glipizide | Glipizide | 86 | 28 |
| Allopurinol | Allopurinol | 85 | 27 |
| Bupropion Xl | Bupropion Hcl | 80 | 20 |
| Potassium Chloride | Potassium Chloride | 77 | 19 |
| Montelukast Sodium | Montelukast Sodium | 75 | 20 |
| Sertraline Hcl | Sertraline Hcl | 75 | 24 |
| Lorazepam | Lorazepam | 72 | 16 |
| Methylprednisolone | Methylprednisolone | 70 | 62 |
| Eliquis | Apixaban | 65 | 18 |
| Fenofibrate | Fenofibrate | 64 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Atenolol | Atenolol | 63 | 20 |
| Meloxicam | Meloxicam | 62 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 16 |
| Ezetimibe | Ezetimibe | 58 | 16 |
| Buspirone Hcl | Buspirone Hcl | 57 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 14 |
| Carvedilol | Carvedilol | 56 | 19 |
| Xarelto | Rivaroxaban | 53 | 15 |
| Azithromycin | Azithromycin | 52 | 50 |
| Jardiance | Empagliflozin | 50 | 11 |
| Spironolactone | Spironolactone | 47 | 16 |
| Valsartan | Valsartan | 45 | 16 |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 14 |
| Ozempic | Semaglutide | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 11 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Famotidine | Famotidine | 36 | 12 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Baclofen | Baclofen | 35 | 24 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Testosterone | Testosterone | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Diazepam | Diazepam | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Fluconazole | Fluconazole | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Estradiol | Estradiol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 11 |
| Dutasteride | Dutasteride | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | 11 |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.03 · 7 records | Exact Sciences Corporation | AIRSUPRA, CAPVAXIVE, Cologuard Collection Kit, MOUNJARO, OTEZLA, REPATHA, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error